Eptinezumab significantly reduced headache and migraine days even in treatment-resistant patients, but effectiveness dropped from 79% response in CGRP-naive patients to 24% in those who had failed three prior CGRP antibodies.
79% → 24% responseResponse to eptinezumab dropped from 79% in patients naive to CGRP antibodies to just 24% in those who had already failed three other CGRP antibodies
What the researchers found
Eptinezumab 100 mg significantly reduced MHD, MMD, and AMD in both EM and CM patients. The 30% MHD responder rate strongly correlated with prior CGRP antibody failure: 78.6% (no prior CGRP mAb), 45.0% (failed 1), 32.1% (failed 2), 23.5% (failed 3), p=0.010. Only 10.4% reported mild side effects.
Why it matters
Many migraine patients cycle through multiple CGRP antibodies without adequate relief. This study provides the first real-world data on whether switching to eptinezumab (IV route) helps after other CGRP antibodies fail — important information for clinicians making difficult treatment decisions in refractory migraine.
The numbers in context
Not specified in abstract — multicentre data from German clinical practice.
How the study worked
Retrospective real-world analysis of 79 patients (EM n=19, CM n=60) across four German centres. All treated with eptinezumab 100 mg IV. Endpoints: MHD, MMD, and AMD changes at 3 months. Response correlated with number of prior CGRP antibody failures. Bonferroni-corrected significance level α=0.017.
Who was studied
Treatment-resistant migraine patients in German clinical practice
What this study cannot tell us
Small sample (79 patients). Retrospective design. Only 3-month follow-up. Only the lower eptinezumab dose (100 mg) was used; 300 mg might show better results. German reimbursement policy creates selection bias — eptinezumab was mostly used as last resort. No blinding or control group.
How to read the evidence
Rated moderate: multi-centre real-world data addressing an important clinical question, but limited by small sample, retrospective design, short follow-up, and only testing the lower dose.
When this study was published
Published in 2024. Among the first studies to examine CGRP antibody switching patterns and cross-resistance in real-world practice.
The bigger picture
This study addresses a crucial clinical question: does switching between CGRP-targeting antibodies help? The declining response rates with each prior failure suggest partial cross-resistance within the CGRP antibody class, but the fact that nearly 1 in 4 patients still respond after three failures argues for giving eptinezumab a chance.
Questions still open
- Would the higher 300 mg dose of eptinezumab show better response rates in patients who failed other CGRP antibodies?
- Is there a biomarker that could predict which multi-failure patients will still respond to eptinezumab?
- Does the IV administration route (vs subcutaneous) offer any mechanistic advantage, or is it simply a formulation difference?
Common questions
Should I try eptinezumab if other CGRP antibodies didn't work for my migraines?
How is eptinezumab different from other CGRP migraine treatments?
Read the original research
Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany.
The journal of headache and pain, 25(1), 79
Citation
Scheffler, Armin; Wenzel, Pauline; Bendig, Merle; Gendolla, Astrid; Basten, Jale; Kleinschnitz, Christoph; Nsaka, Michael; Lindner, Diana; Naegel, Steffen; Burow, Philipp; Fleischmann, Robert; Holle, Dagny. (2024). Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany.. The journal of headache and pain, 25(1), 79. https://doi.org/10.1186/s10194-024-01788-1